Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
102.00    -1.20 (-1.16%)
Bid:
101.40
Ask:
102.20
Spread: 0.80 (0.789%)
Market Cap: £167.22m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Trading Statement

27 Jun 2012 07:00

RNS Number : 2108G
Yule Catto & Co PLC
27 June 2012
 



27 June 2012

 

Yule Catto & Co plc (the "Group") 

 

Pre-Close Trading Update

 

Yule Catto & Co plc ("Yule Catto" or the "Group"), the international producer of speciality chemicals, today issues a trading update in advance of entering its close period.

 

The challenging trading conditions outlined at the time of the Group's May Interim Management Statement have continued through the remainder of the first half of the year.

 

In our Europe and North America business segment, demand remains subdued, driven by continuing economic uncertainty and its effect on general business confidence. Demand is currently a little weaker than the first few months of the year, with business in the construction related sector continuing to be the weakest area of activity. Margin management has fully compensated for the volume declines, and our European business is benefitting from the synergies of the PolymerLatex acquisition at the expected levels.

 

In Asia and ROW, the Group's non-nitrile businesses are performing well. In nitrile, the weakness in end market demand continues. This, combined with the effect of recent capacity additions has led to increasingly aggressive competitor pricing and a further weakening of profitability in nitrile. Additional competitive capacity is also due on stream during the course of the summer. The Board remains confident in the long term value that the Group will derive from this high growth sector. However, given the overall supply demand position, competitive behaviour and the volatility in trading caused by rapidly changing input prices, the Board now anticipates the current weakness in nitrile will probably continue throughout the remainder of this year and into next year. This will substantially lower operating profit in our Asia and ROW business segment while this persists.

 

The impact of currency remains uncertain, with the volatility in the euro. Based on current exchange rates, the Board anticipates a reduction to operating profit of some £5 million from translation consistent with the guidance on currency issued with the Group's IMS in May.

 

While the combination of weakness in nitrile and currency translation effects will impact the Group's performance, the Board still anticipates that full year underlying profit before tax will be ahead of prior year pro-forma.

 

Yule Catto will announce interim results for the six months to 30 June 2012 on Tuesday 28 August 2012.

 

Ends

 

 Enquiries:

 

 

Yule Catto & Co plc

Tel: 01279 442791

Adrian Whitfield, Chief Executive

 

David Blackwood, Group Finance Director

 

 

 

 

MHP Communications

Tel: 020 3128 8100

Andrew Jaques

 

John Olsen

 

Naomi Lane

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTSESFAMFESESM
Date   Source Headline
4th Sep 20203:15 pmRNSDirector Declaration
6th Aug 20207:00 amRNSInterim Results for six months ended 30 June 2020
27th Jul 202010:00 amRNSPost Stabilisation Notice
16th Jul 20207:00 amRNSAppointment of Non-Executive Director
8th Jul 20204:16 pmRNSHolding(s) in Company
8th Jul 20204:14 pmRNSHolding(s) in Company
19th Jun 20207:00 amRNSSynthomer announces the pricing of senior notes
16th Jun 202011:54 amRNSPre Stabilisation Notice
16th Jun 202010:11 amRNSQ2 trading update
11th May 20205:21 pmRNSHolding(s) in Company
11th May 20209:03 amRNSDirector/PDMR Shareholding
11th May 20209:02 amRNSDirector/PDMR Shareholding
11th May 20208:59 amRNSDirector/PDMR Shareholding
11th May 20208:58 amRNSDirector/PDMR Shareholding
29th Apr 20203:17 pmRNSResult of AGM
29th Apr 20207:00 amRNSQ1 Trading and COVID-19 Update
1st Apr 20202:44 pmRNSCompletion of OMNOVA acquisition
1st Apr 20207:00 amRNSAnnual Financial Report
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
30th Mar 20207:00 amRNSAppointment of Deputy Chair and Chair-elect
30th Mar 20207:00 amRNSDirector/PDMR Shareholding
26th Mar 202010:17 amRNSEuropean Commission clearance for OMNOVA
23rd Mar 20207:00 amRNSDirector/PDMR Shareholding
16th Mar 20209:50 amRNSDirector/PDMR Shareholding
13th Mar 20205:29 pmRNSDirector/PDMR Shareholding
9th Mar 20202:45 pmRNSHolding(s) in Company
5th Mar 20207:00 amRNSPreliminary Results for the year ended 31 Dec 2019
31st Jan 20209:36 amRNSDirector Declaration
15th Jan 20202:21 pmRNSAcquisition of OMNOVA receives EC clearance
6th Dec 20197:00 amRNSAppointment of Broker
13th Nov 20192:53 pmRNSDirector/PDMR Shareholding
11th Nov 20197:00 amRNSDirector Declaration
25th Oct 20197:00 amRNSQ3 Trading Update
22nd Oct 20197:00 amRNSAGM Statement
11th Oct 20197:00 amRNSOmnova shareholders approval
14th Aug 20193:25 pmRNSHolding(s) in Company
13th Aug 201912:33 pmRNSDirector/PDMR Shareholding
6th Aug 20197:00 amRNSInterim Results for 6 months ended 30 June 2019
2nd Aug 201910:29 amRNSHolding(s) in Company
1st Aug 20199:05 amRNSHolding(s) in Company
31st Jul 201910:51 amRNSResults of Extraordinary General Meeting
30th Jul 20191:07 pmRNSDirector/PDMR Shareholding
30th Jul 20191:03 pmRNSDirector/PDMR Shareholding
30th Jul 20191:02 pmRNSDirector/PDMR Shareholding
30th Jul 20191:01 pmRNSDirector/PDMR Shareholding
30th Jul 201912:59 pmRNSDirector/PDMR Shareholding
30th Jul 201912:57 pmRNSDirector/PDMR Shareholding
30th Jul 201912:57 pmRNSDirector/PDMR Shareholding
30th Jul 201912:55 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.